Neurogene Inc. (NGNE)
NGM · Healthcare · Biotechnology
$35.48
-1.77%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$710.0M
Shares Outstanding
20.0M
Exchange
NGM
Currency
USD
About Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (23.8M) | (27.5M) | (33.3M) | (36.7M) |
| Net Income | (21.0M) | (24.7M) | (30.9M) | (34.5M) |
| Diluted EPS | $-0.99 | N/A | $-1.39 | $-1.53 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 925K | 0.00 |
| Operating Income | (56.5M) | (55.6M) | (82.6M) | (103.3M) |
| Net Income | (55.2M) | (36.3M) | (75.1M) | (90.4M) |
| Diluted EPS | $-37.80 | $-73.83 | $-4.28 | N/A |